Objectives: Gastroesophageal reflux disease (GERD) is common and often treated with proton pump inhibitors (PPIs) or H2-receptor antagonists (H2-RAs). GERD has been associated with exposure of the middle ear to gastric contents, which could cause hearing loss. Treatment of GERD with PPIs and H2-RAs may decrease exposure of the middle ear to gastric acid and decrease the risk of hearing loss. We prospectively investigated the relation between GERD, use of PPIs and H2-RAs, and the risk of hearing loss in 54,883 women in Nurses' Health Study II. Conclusions: GERD symptoms are associated with higher risk of hearing loss in women, but use of PPIs and H2-RAs are not independently associated with the risk.
INTRODUCTION
Hearing loss is the most common sensory disorder and is highly prevalent among adults in the United States (Agrawal et al. 2008) . Although the prevalence of high-frequency hearing loss is lower in women compared with men, it affects one-third of women in their 50s and close to two-thirds of women in their 60s (Agrawal et al. 2008) . The adverse impact of hearing loss on an individual's quality of life can be considerable (Cacciatore et al. 1999; Olusanya et al. 2006) , thus identifying potential modifiable risk factors for hearing loss is important.
Gastroesophageal reflux disease (GERD) is also common and affects approximately 10-20% of people in the Western world (Dent et al. 2005) . The mainstays of medical therapy for patients with GERD are proton pump inhibitors (PPIs) and H2-receptor antagonists (H2-RAs), with some studies suggesting PPIs are more effective than H2-RAs (Bate et al. 1990; Chiba et al. 1997) . GERD may lead to exposure of the middle ear to gastric enzymes, which in mouse models has been associated with Eustachian tube dysfunction, impaired clearance of middle ear contents, and hearing loss (Heavner et al. 2001; White et al. 2002; Develioglu et al. 2013; Yüksel et al. 2013) .
Treatment of GERD with PPIs or H2-RAs may decrease exposure of the middle ear to gastric acid, thereby decreasing the risk of hearing loss. PPIs inhibit the hydrogen/potassium adenosine triphosphate enzyme system of gastric parietal cells, thereby inhibiting secretion of hydrogen ions into the gastric lumen. This enzyme is also expressed in the lateral wall of the cochlea (Lecain et al. 2000) and plays a critical role in formation of the endocochlear potential (Shibata et al. 2006) . Thus, inhibition of this enzyme by PPI treatment could increase the risk of hearing loss. H2-RAs are competitive antagonists of gastric parietal cell H2-receptors, which suppress normal secretion of hydrogen ions. Use of H2-RAs is not known to influence inner ear function.
Although GERD and its treatment with PPIs and H2-RAs are common, the relation between GERD, these medications, and hearing loss has not been prospectively examined. Thus, we investigated the relation between GERD, regular use of PPIs and H2-RAs, and hearing loss in a prospective cohort of 54,883 women in the Nurses' Health Study II.
MATERIALS AND METHODS

Study Participants
The Nurses' Health Study II is a cohort of 116,430 female registered nurses originally enrolled in 1989 who were aged 25 to 42 years. Participants were aged 41 to 58 years in 2005 (the baseline year for our analysis). Questionnaires are administered biennially, with an average follow-up rate exceeding 90% of the eligible person-time. These biennial questionnaires assess participants' dietary habits, lifestyle habits, and medical history. They are available at the following website: http://www.nurseshealthstudy. org/participants/questionnaires. The majority of the women in the cohort are non-Hispanic whites, with a small percentage being Asian-American (2%), African-American (2%), and Hispanic 
Ascertainment of GERD Symptoms
On the 2005 questionnaire, women were asked for the first time whether they had ever regularly had heartburn/acid reflux one or more times a week. If they answered "yes," they were asked how long this has been occurring (5 years or less, 6 to 14 years, and 15 years or longer), and how often they had symptoms in the past year (none in the last year, less than once a month, once a month, about once a week, several times a week, or daily). In 2009, GERD status was updated when participants were again asked how often they had heartburn or acid reflux. Our analysis examined self-reported GERD symptoms (yes versus no), as well as frequency and duration of symptoms. Women who answered the question on GERD symptoms but did not specify frequency or duration of symptoms were excluded from the analysis by GERD symptom frequency and duration.
Ascertainment of Medication Use
On the 2003 questionnaire and every 2 years thereafter, women were asked whether they regularly used PPIs or H2-RAs. Our analysis examined regular usage of PPIs or H2-RAs starting in 2005. If information on PPI or H2-RA use was missing for a 2-year time period, person-time for that participant was not included for that time period.
Ascertainment of Hearing Loss
The outcome examined in this study was self-reported hearing loss. Participants were asked in 2009, "Do you have a hearing problem?," and if so, "At what age did you first notice a change in your hearing?." In 2013, participants were again asked about their hearing. We defined incident cases of hearing loss as participants who reported a hearing problem (a little hearing trouble, moderate hearing trouble, or deaf) that was first noticed after 2005.
The gold standard of evaluating hearing loss is pure-tone audiometry. Because it is costly and logistically challenging to obtain audiometric tests on all study participants, self-reported hearing loss has been used successfully in several large population-based studies. Studies have found a single question on self-reported hearing loss to be a relatively reliable indicator of hearing loss (Nondahl et al. 1998) . The sensitivities and specificities for detecting hearing loss range from 77 to 100% and 70 to 84%, respectively (Gomez et al. 2001; Hannula et al. 2011; Salonen et al. 2011; Swanepoel de et al. 2013 ). Significant associations have been observed between several factors and risk of self-reported hearing loss assessed in this manner in Nurses' Health Study II (Curhan et al. 2012 (Curhan et al. , 2013 (Curhan et al. , 2014 .
Ascertainment of Covariates
Covariates were selected based on previously reported risk factors for hearing loss. Factors considered included age (Agrawal et al. 2008) , race (Agrawal et al. 2008) , body mass index (Seidman 2000; Curhan et al. 2013) , waist circumference (Curhan et al. 2013) , alcohol consumption (Itoh et al. 2001; Curhan et al. 2014) , diet [folate (Durga et al. 2007 ), vitamin A (Le Prell et al. 2007 ), vitamin B 12 (Houston et al. 1999) , vitamin C, vitamin E, potassium (Wangemann 2006) , magnesium (Haupt et al. 2003) , trans fats, omega-3 fatty acids (Curhan et al. 2014) , beta-carotene, and beta cryptoxanthin], physical activity (Li et al. 2006; Curhan et al. 2013) , smoking (Itoh et al. 2001) , diabetes (Bainbridge et al. 2008) , hypertension (Lin et al. 2016) , tinnitus (Nondahl et al. 2002; Hasson et al. 2010 ), diuretic (thiazides or furosemide) use (Gallagher et al. 1979) , and analgesic (acetaminophen, aspirin, and ibuprofen) use (Curhan et al. 2012) .
Data on covariates were obtained from the biennial questionnaires. Women were asked in 2005 whether they described themselves as white, black/African-American, Asian, Native American/Alaska Native, Native Hawaiian/Pacific Islander, or other. Nutritional intake (alcohol, folate, vitamin A, vitamin B 12 , vitamin C, vitamin E, potassium, magnesium, trans fats, omega-3 fatty acids, beta-carotene, and beta-cryptoxanthin) was derived from semiquantitative food frequency questionnaires mailed to study participants every 4 years. Information derived from the semiquantitative food frequency questionnaire in 2003 was used in our analysis and updated in 2007. The validity and reproducibility of these questionnaires has previously been reported (Willett et al. 1985; Rimm et al. 1992 ). In addition, the validity of covariate data provided by this cohort or other similar cohorts has been shown to be reliable in previous studies (Willett et al. 1985; Colditz et al. 1986; Rimm et al. 1990 Rimm et al. , 1992 Wolf et al. 1994 ).
Statistical Analysis
All analyses were performed in a prospective manner using information on GERD symptoms and medication use that was collected before the report of hearing loss onset. Participants were censored at the time of cancer diagnosis. Multivariable-adjusted relative risks were calculated using Cox proportional hazards regression models. The Anderson-Gill data structure was used to handle left truncation and time-varying covariates efficiently (Therneau et al. 2000) . To control as finely as possible for confounding by age, calendar time, and any possible two-way interactions between these two time scales, we stratified the analysis jointly by age at start of the follow-up and calendar year of the current questionnaire cycle. We performed analyses stratified by frequency of GERD symptoms to examine whether the association between PPI use and H2-RA use with hearing loss differed by these factors. Duration of GERD symptoms was only asked in 2005; however, if participants answered the question on duration of symptoms in 2005, symptom duration was updated based on responses to the question on GERD in 2009. If participants reported GERD symptoms for the first time in 2009, they were assigned a symptom duration of 2 years. , and ≥40 kg/m 2 , and waist circumference was categorized as (<71 cm, 71 to 79 cm, 80 to 88 cm, >88 cm). Nutrients were categorized as quintiles of daily intake or in prespecified categories. All p values are two sided, with 95% confidence intervals (CIs) calculated for all relative risks. SAS software, version 9.4 (SAS Institute Inc., Cary, NC) was used to perform all statistical analyses.
RESULTS
The characteristics of participants at baseline according to self-reported GERD symptom status, PPI use, and H2-RA use are shown in Table 1 . Women who reported having GERD symptoms had higher body mass index, had higher waist circumference, were less physically active, were more likely to be past or current smokers, and were more likely to have a history of hypertension and diabetes.
At baseline (2005), 18,157 women (33%) reported having GERD symptoms. Of the women with GERD symptoms, 2679 (15%) were taking PPIs alone, 1018 (6%) were taking H2-RAs alone, and 115 (1%) were taking both PPIs and H2-RAs.
During 361,872 person-years of follow-up, 9842 cases of hearing loss were reported. Compared with participants who reported no GERD symptoms in the past year, the multivariableadjusted relative risk of hearing loss was higher with increasing frequency of GERD symptoms (daily GERD symptoms multivariable-adjusted relative risk = 1.33; 95% CI = 1.19, 1.49; p value for trend <0.001; Table 2 ). Compared with participants who reported no GERD symptoms in the past year, the multivariable-adjusted relative risk of hearing loss was higher with increasing duration of GERD symptoms (15 or more years of symptoms multivariable-adjusted relative risk = 1.20; 95% CI = 1.10, 1.32; P for trend <0.0001; Table 3 ). Gamma statistic between frequency of GERD symptoms and duration of GERD symptoms was 0.89 (p = 0.001). The biggest confounders were body mass index and waist circumference.
Before taking into account GERD symptoms, PPI use was independently and significantly associated with increased risk of hearing loss (multivariable-adjusted relative risk = 1.16, 95% CI = 1.08, 1.24), but H2-RA use was not (multivariable-adjusted relative risk = 1.10, 95% CI = 0.97, 1.24). After taking into account GERD symptoms, there was no significant association between PPI use and hearing loss (Table 4 ). There was no significant association between H2-RA use and hearing loss in any stratum (Table 4) .
Adjusting for body mass index and waist circumference as continuous variables did not materially change the results. After excluding participants with a history of tinnitus, the results were not materially changed for GERD symptoms, PPI use, or H2-RA use (data not shown).
DISCUSSION
In this large prospective study of women, increasing frequency and duration of GERD symptoms were independently associated with a higher risk of hearing loss. However, use of PPIs or H2-RAs was not associated with hearing loss after accounting for GERD symptoms.
Recent studies have shown evidence of gastric contents in middle ear effusions of children with recurrent otitis media (McCoul et al. 2011 ). Animal models suggest that exposure of the middle ear to gastric contents may cause Eustachian tube dysfunction, impaired mucociliary clearance of middle ear contents, and sensorineural hearing loss (Heavner et al. 2001; White et al. 2002; Develioglu et al. 2013; Yüksel et al. 2013) .
The mechanism by which GERD may increase the risk of hearing loss is unclear. Exposure of the inner ear to gastric contents via diffusion or active transport of gastric contents through the round window membrane, which has been shown to occur with several other compounds, may result in damage to the inner ear and sensorineural hearing loss (Schuknecht 1957; Richardson et al. 1971; Miriszlai et al. 1978; Kim et al. 1990 ). Alternatively, exposure of the round window membrane to gastric contents may result in increased permeability of this membrane, as is the case with middle ear infections, making the inner ear more susceptible to damage (Ikeda et al. 1988; Ikeda et al. 1990 ). However, the pathophysiology is not well understood and warrants further investigation. Previous studies in rodent models have demonstrated that PPIs inhibit the hydrogen/potassium adenosine triphosphate enzyme system in the lateral wall of the cochlea (Lecain et al. 2000) , thereby inhibiting formation of the endocochlear potential (Shibata et al. 2006) . Conversely, in people with GERD, PPI use may decrease exposure of the middle ear to gastric acid and decrease risk of hearing loss. Although PPI use was associated with an increased risk of hearing loss in our study before accounting for frequency of GERD symptoms, there was no overall association between PPI use and hearing loss after accounting for GERD symptom frequency, an example of confounding by indication. We observed no relation between use of H2-RAs and hearing loss.
Our study has limitations. The study population was predominantly non-Hispanic white women. Although this cohort of women may not be representative of the United States adult female population, information provided by this cohort is highly reliable and the follow-up rates are high. Further investigation is needed to examine these associations in other populations. Our data are dependent on the accuracy of participants' self-report. However, the validity of information on a variety of exposures provided by this cohort of women has been shown to be reliable in previous studies (Willett et al. 1985; Colditz et al. 1986; Rimm et al. 1990 Rimm et al. , 1992 Wolf et al. 1994) . Assessment of GERD symptoms was based on self-reported frequency of symptoms. Given the high between frequency of GERD symptoms and duration of GERD symptoms, we were unable to ascertain whether the risk of hearing loss is independently associated with frequency of GERD symptoms, duration of GERD symptoms, or both. The outcome of our study was self-reported hearing loss. Although pure-tone audiometry is considered the gold-standard for evaluation of potential hearing loss and allows for differentiation between conductive and sensorineural hearing loss, self-reported hearing loss has been shown to be a reliable indicator of hearing loss (Gomez et (folate, vitamin A, vitamin B 12 , vitamin C, vitamin E, magnesium, potassium, beta-carotene, beta-cryptoxanthin, trans United States Preventive Services Task Force on the accuracy of screening tools for hearing loss revealed that a single question about perceived hearing loss was almost as accurate as a more detailed questionnaire or portable audiometric device in hearing loss detection (Chou et al. 2011) . Although there may be residual confounding, we adjusted as finely as possible for many known risk factors for hearing loss. We did not have information on frequency of PPI or H2-RA use.
In conclusion, higher frequency and duration of GERD symptoms is associated with a higher risk of hearing loss in women. No relation was observed between PPI use or H2-RA use and hearing loss after accounting for GERD symptoms. Given the high prevalence of GERD symptoms in the general population, these findings suggest a common modifiable risk factor may contribute to the development of hearing loss.
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